A panel on women’s health disparities at the 2023 Asembia Specialty Pharmacy Summit addressed the current challenges women face regarding health care as well as how digital tools, collaboration between clinics and governments, and more detailed and inclusive research can help improve health equity for all women.
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses the role the new wave of biosimilars will have on rebate practices for both pharmacy benefit managers (PBMs) and payers.
An expert panel at the recent meeting of the Quality Cancer Care Alliance discussed the Enhancing Oncology Model (EOM), which is set to begin on July 1, 2023.
Jessica Robinson-Papp, MD, MS, professor of neurology at Icahn School of Medicine at Mt. Sinai, talks about what factors can contribute to medication nonadherence in people with HIV, and the different levels of support that might be available to patients.
Sebastian Pistritto, chief marketing officer at ParcelShield Holdings, LLC, talks about how technology such as artificial intelligence helps to evaluate data to assist in medication delivery service decision-making, depending on the need of the pharmacy and its patients.
Neal Dave, PharmD, executive director of pharmacy operations at Texas Oncology, discusses updates to the National Community Oncology Dispensing Association (NCODA) Center of Excellence pharmacy accreditation program.
The 2023 Asembia Specialty Pharmacy Summit featured Juliana (Julie) Reed, executive director of the Biosimilars Forum, who spoke on the challenges still facing the biosimilars industry and how they may impact the success of adalimumab biosimilars in the United States.
David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, discusses the importance of patient safety in a first-in-human trial of NRTX-1001 GABAergic interneuron cell therapy for focal epilepsy.
A panel at Asembia 2023 discussed what their organizations are doing to improve diversity, equity, and inclusion (DEI) at their organizations, and what others can learn from these efforts.
Naveen Mansukhani, director of operations and account management of Retail Pharmacy Services at Cardinal Health, talks about how the responsibility for saving costs does not just fall on one department or person, but is collaborative and requires strategy.
Connie Sullivan, president and CEO of the National Home Infusion Association (NHIA), discusses why at-home infusion is beneficial to patients and why so many patients reported feeling satisfied with home administration.
David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, talks about the first-in-human trial of interneuron cell therapy for treatment of focal epilepsy and explains the next steps.
Although digital tools can be immensely helpful for creating a personalized, convenient interaction between patients and the health care system, they should not be the end-all be-all method to improve the patient experience, according to a panel discussion at the 2023 Asembia Specialty Pharmacy Summit.
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what's to come as a result of a "second wave" of biosimilars hitting the market.
Technology and automation within patient assistance programs can enhance the patient journey and assist pharmaceutical manufacturers at a lower cost, explained Josh Marsh, vice president of Sonexus at Cardinal Health.
At the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, provided updates to the 2023 specialty therapy pipeline.
In a panel at the 2023 Asembia Specialty Pharmacy Summit, speakers presented on the payer perspective regarding biosimilars, including that they feel comfortable preferring multiple biosimilars for the same reference product and are looking for interchangeability designations.
Reducing disparities in the treatment of atopic dermatitis (AD) was the focus of a session of the final day of the Revolutionizing Atopic Dermatitis 2023 conference.
Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses the use of systemic therapies vs biologics and why adherence is so important when treating patients with atopic dermatitis (AD).
Larry Eichenfield, MD, professor of dermatology and pediatrics and vice chair of the Department of Dermatology at the University of California San Diego School of Medicine and chief of pediatric and adolescent dermatology at Rady Children's Hospital San Diego, discusses the use of different treatments and biologics for atopic dermatitis (AD) in infants, which he presented at the Revolutionizing Atopic Dermatitis conference.
Panelists at the 2023 Asembia Specialty Pharmacy Summit discussed the myriad of ways that the drug pricing policies of the Inflation Reduction Act (IRA), such as inflation rebates and a redesign of Medicare Part D plans, will affect payers and manufacturers.
A panel held at Revolutionizing Atopic Dermatitis 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.
Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.
Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses treatment approaches for atopic dermatitis of the face in infancy, which he presented at the Revolutionizing Atopic Dermatitis conference.
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference.
In posters presented at the Revolutionizing Atopic Dermatitis conference, ruxolitinib cream was found to be both safe and effective in treating atopic dermatitis (AD).
Craig D. Pederson, principal at Insight Health Care Partners, discussed the evolving landscape of value-based care and challenges to implementation from the provider perspective during his keynote presentation at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.
A session led by Irina Koyfman, DNP, NP-C, RN, at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023 detailed the potential of chronic care management billing for physicians who are not currently doing it and recommendations for optimizing the process.
Todd A. Zigrang, MBA, MHA, FACHE, CVA, ASA, ABV, president of Health Capital Consultants, discusses accountable care organizations (ACOs) and the move toward value-based care models.
Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, discusses the importance of biomarker testing in non–small cell lung cancer (NSCLC).
